Revier Therapeutics develops small-molecule therapies for cardiometabolic diseases.
Revier Therapeutics has raised $7.0M in total funding. The most recent round was Seed. The last funding was announced in August 2026.
Revier Therapeutics's investors include HTGF (High-Tech Gruenderfonds), KHAN Technology Transfer Fund, VORNvc.
Revier Therapeutics is headquartered in Deidenberg, Belgium.
Revier Therapeutics develops small-molecule therapies for cardiometabolic diseases.
Revier Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Revier Therapeutics — Funding & Investors." VCBacked, August 25, 2026, https://www.vcbacked.co/company/revier-therapeutics. Accessed September 9, 2026.
VCBacked. (2026). Revier Therapeutics — Funding & Investors. Retrieved September 9, 2026, from https://www.vcbacked.co/company/revier-therapeutics
{{cite web |title=Revier Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/revier-therapeutics |website=VCBacked |access-date=September 9, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated